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Background: Plasma low density lipoprotein (LDL) particles vary in size, density, electrical charge and chemical
composition. An increased presence of small dense LDL (sdLDL), along with raised triglyceride concentrations and
decreased high density lipoprotein (HDL) cholesterol concentrations is commonly known as the atherogenic triad
and has been observed in some cases of obesity, principally in Europe and America. This study examines the
prevalence of sdLDL in the plasma of an obese (BMI ≥ 25 kg/m2) Thai population.
Methods: Plasma from fasted obese (n = 48) and non-obese (n = 16) Thai participants was subjected to density
gradient ultracentrifugation in iodixanol to separate lipoproteins. Gradients were unloaded top-to-bottom into
20 fractions which were assayed for cholesterol, triglyceride, apo B and apo A-1 to identify lipoprotein types
and subtypes.
Results: LDL cholesterol was subfractionated into LDL I + II (fractions 3–6, ρ = 1.021-1.033 g/ml) which was
considered to represent large buoyant LDL (lbLDL), LDL III (fractions 7–9, ρ = 1.036-1.039 g/ml) which was
considered to represent sdLDL, and, LDL IV (fractions 10–12, ρ = 1.044-1.051 g/ml) which was considered to
represent very sdLDL. Concentrations of LDL III and IV were increased by 15-20% in obese participants whilst
that of LDL I + II was concomitantly decreased by 10%. This was accompanied by a 50% increase in plasma
triglyceride concentrations and 15% decrease in HDL cholesterol concentrations. Only 3/16 (19%) non-obese
participants had a pattern B LDL cholesterol profile (peak density of >1.033 g/ml), whilst 28/48 (58%) obese
participants were pattern B. When expressed as a fraction of the LDL concentration, total sdLDL (i.e. LDL III + IV)
showed highly significant correlations to plasma triglyceride concentrations and the triglyceride/HDL cholesterol ratio.
Conclusions: The prevalence of sdLDL is increased in obesity in a Thai population such that they demonstrate a similar
atherogenic triad to that previously observed in European and American populations.
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Obesity is an increasing worldwide health concern, and a
known risk factor for several chronic diseases including
type-2 diabetes, cardiovascular disease, skeletal disorders
and some cancers [1-5]. Whilst a body mass index (BMI)
of ≥30 kg/m2 is generally accepted to define obesity in
Europe and North America, a lower threshold of 25 kg/
m2 is more appropriate to define obesity in Thai and
south-east Asian populations [6-9]. Indeed, a recent
study has proposed a BMI cut-off of 23 or 24 kg/m2 for* Correspondence: i.g.davies@ljmu.ac.uk
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unless otherwise stated.Thai men and women respectively to predict at least one
cardiovascular risk factor [10].
LDL consists of a continuum of particles varying in size,
density, electrical charge, and chemical (lipid and apo-
protein) composition. Density gradient ultracentrifugation
in high concentrations of salt (usually KBr) was originally
used to identify and quantitate LDL subclasses in plasma.
Using this method, four LDL subclasses were identified in
the density range 1.019-1.060 g/ml; namely LDL-I (large
buoyant, 1.019-1.023 g/ml), LDL-II (intermediate, 1.024-
1.034 g/ml), LDL-III (small dense, 1.034-1.044 g/ml) and
LDL-IV (very small dense, 1.044-1.060 g/ml) [11,12].
Krauss and colleagues have simplified this to define
two LDL phenotypes; so-called pattern A individualstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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LDL (lbLDL) in plasma whilst pattern B individuals have a
predominance of small dense LDL (sdLDL) [12,13].
Some studies have observed an increased presence of
sdLDL particles in the plasma of obese participants
[14,15]. This is associated with raised plasma triglyceride
concentrations and decreased HDL-cholesterol concen-
trations, forming the so-called ‘atherogenic lipid triad’
[16]. sdLDL is more atherogenic partly because it has a
lower affinity for the LDL receptor and hence remains in
the circulation longer, but also because its lipid and
protein components are more prone to chemical modifi-
cation (e.g. oxidation or glycation) and uptake by scaven-
ger receptors [17]. Indeed, it has been estimated that
participants with raised sdLDL concentrations have an
approximate 3- to 7-fold increase in risk of developing
coronary heart disease [18].
Whilst an increased prevalence of sdLDL has been
associated with obesity in a variety of populations, this
has not been investigated in Thai populations, and this
was the primary aim of this study. Density gradient
ultracentrifugation in iodixanol was used as this allowed
the identification and quantitation of all LDL subclasses,
not just sdLDL. Iodixanol is an iso-osmotic, iodinated
compound (Mr 1550) which has been used to separate
LDL subclasses by density gradient ultracentrifugation
[19,20]. It has the advantage over high concentrations of
KBr in that density gradients can be generated during aTable 1 Characteristics of plasma lipids in obese and non-obe
Non-obese
(BMI < 25 kg/m2)
n (%) 16 (25.0)
Sex (M/F) 8/8
Age (year) 46.3 ± 12.6
Total cholesterol (mmol/L) 5.18 ± 1.03
Triglyceride (mmol/L) 1.04 ± 0.55
VLDL-C (mmol/L) 0.30 ± 0.12
LDL-C (mmol/L) 2.90 ± 0.89
LDL I + II (mmol/L) 1.56 ± 0.41
LDL III (mmol/L) 1.05 ± 0.43
LDL IV (mmol/L) 0.27 (0.19-0.31)
LDL I + II /LDL 0.55 ± 0.06
LDL III /LDL 0.36 ± 0.05
LDL IV /LDL 0.09 ± 0.02
HDL-C (mmol/L) 1.43 ± 0.25
Apo-A1 (g/L) 1.42 ± 0.27
Apo-B (g/L) 0.86 ± 0.24
Data are n (%) or mean ± SD or median (interquartile range). BMI, body mass index;
cholesterol; LDL I + II, low-density lipoprotein subclasses I and II; LDL III, low-density
high-density lipoprotein cholesterol. Means were compared between non-obese an
were calculated from Mann–Whitney U test. P-values were adjusted for age and gecentrifuge run and, when carried out in a vertical or
near-vertical rotor, results in much shorter centrifuge
run times of 2–3 hours.
Results
Of the 64 Thai participants recruited to the study, 48
(75%) had a BMI ≥ 25 kg/m2 and hence were classed as
obese (Table 1). Both obese and non-obese participants
had similar ages and plasma total cholesterol concentra-
tions were similar in both groups whilst plasma trigly-
ceride concentrations were significantly increased by
approximately 50% in obese compared to non-obese par-
ticipants (Table 1).
Ultracentrifugation of plasma in self-generating gradi-
ents of iodixanol allowed separation of lipoproteins into
their constituent types and subtypes. Under the condi-
tions used in this study, LDL was identified as a broad
peak of cholesterol (Figure 1a) and triglyceride (Figure 1b)
between fractions 3–12 at a density of 1.021-1.051 g/ml.
Apo-B, the principal apo-protein associated with LDL,
showed exactly the same profile in fractions 3–12 of the
gradients (Figure 1c). A second broad peak of cholesterol
(Figure 1a) and triglyceride (Figure 1b) between fractions
13–20 was identified as HDL and occurred at density
1.057-1.161 g/ml (Figure 1a); this was confirmed by apo-
A1 having a similar distribution profile (Figure 1d). Partic-
ipants fasted before venipuncture, when chylomicrons
would be expected to be absent. Thus, the large amountse Thai participants
Obese p value Adjusted
p value(BMI ≥25 kg/m2)
48 (75.0)
12/36
46.4 ± 11.4 0.980 -
5.24 ± 0.99 0.833 -
1.64 ± 0.59 0.001 0.002
0.42 ± 0.14 0.004 0.010
3.03 ± 0.82 0.612 -
1.37 ± 0.40 0.116 -
1.28 ± 0.41 0.061 -
0.34 (0.27-0.46) 0.003 0.035
0.46 ± 0.07 <0.001 0.002
0.42 ± 0.05 <0.001 0.002
0.12 ± 0.03 <0.001 0.003
1.21 ± 0.22 0.001 0.004
1.22 ± 0.25 0.010 0.014
0.92 ± 0.25 0.390 -
VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
lipoprotein subclass III; LDL IV, low-density lipoprotein subclass IV; HDL-C,
d obese groups by Independent-Sample T test, except LDL IV when p values
nder by Binary Logistic Regression.
a b
c d
Figure 1 Lipid profiles of iodixanol density gradients. Plasma gradient fractions, from obese and non-obese Thai participants, were analysed for
(a) Cholesterol, (b) triglyceride (c) apo-B and (d) apo-A1. Values are means ± SD of 16 non-obese participants (indicated by ●) and 48 obese
participants (indicated by ■). Gradient densities are means ± SD of all 64 gradients (indicated by▲).
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esterol (Figure 1a) present in fractions 1–2 was inter-
preted as VLDL since this lipoprotein is known to carry
mainly triglyceride.
Recovery of cholesterol, triglyceride, apo-B and apo-
A1, expressed as a percentage of that loaded onto the
gradients, was 100.1 ± 4.0%, 90.9 ± 7.7%, 90.6 ± 7.2%
and 88.9 ± 6.4% respectively (mean ± SD of 64 observa-
tions). Plasma VLDL-, LDL- and HDL-cholesterol con-
centrations were calculated by summing recoveries in
fractions 1–2, 3–12 and 13–20 respectively. Plasma
HDL-cholesterol was significantly decreased by 15% in
obese participants compared to non-obese partici-
pants, VLDL-cholesterol was increased by 40% whilst
LDL-cholesterol was unchanged (Table 1). Concentra-
tions of plasma HDL- and LDL-cholesterol derived
from the density gradients showed excellent agree-
ment with those determined by selective precipitation
and the Friedewald equation (data not shown).
LDL cholesterol was further fractionated into:
 LDL I + II (fractions 3–6, ρ = 1.021-1.033 g/ml)
which were considered to represent large buoyant
and intermediate density LDL,
 LDL III (fractions 7–9, ρ1.036-1.039 g/ml) which
was considered to represent sdLDL, and,
 LDL IV (fractions 10–12, ρ = 1.044-1.051 g/ml)
which was considered to represent very sdLDL.Whilst plasma total cholesterol concentrations were
similar in obese and non-obese participants, cholesterol
concentrations of the most dense LDL subclass, namely
LDL IV, were significantly increased by approximately
20% in obese participants (Table 1). Similarly, the chol-
esterol concentration of LDL III was increased by
approximately 15% whilst that of the larger, more buoy-
ant LDL I + II was decreased by approximately 10%, al-
though both of these changes did not reach statistical
significance (Table 1). Thus, there was a marked shift to-
wards LDL of higher density in obese Thai participants
and this was further evidenced in three ways. Firstly,
when expressed as a fraction of total LDL, plasma con-
centrations of LDL I + II subclasses (hereinafter known
simply as large buoyant (lb) LDL) were significantly lower
in obese compared to non-obese participants whilst those
of LDL III and LDL IV subclasses were significantly
increased (Table 1). Secondly, close examination of the
cholesterol and apo-B distribution profiles in fractions 3–
12 of Figure 1a and c shows a marked shift towards a
higher density, equivalent to approximately half of one frac-
tion, in the plasma of obese participants. This effect was
less apparent, although still noticeable, in the triglyceride
profile (Figure 1b). Finally, the density of the cholesterol
peak following density gradient centrifugation in iodixanol
has been used by Davies et al. [20] to identify so-called pat-
tern A (ρ < 1.033 g/ml) and pattern B (ρ ≥ 1.033 g/ml)
individuals. When this was applied to the participants
Table 3 Plasma lipids in pattern A and B participants
Pattern A Pattern B p value Adjusted
p valued < 1.033 d ≥ 1.033
(g/ml) (g/ml)
Sex (M/F) 11/22 9/22 0.711 -
Cholesterol (mmol/L) 4.85 ± 0.72 5.62 ± 1.09 0.001 0.007
Triglyceride (mmol/L) 1.08 ± 0.35 1.93 ± 0.56 <0.001 <0.001
VLDL-C (mmol/L) 0.31 ± 0.11 0.48 ± 0.13 <0.001 <0.001
LDL-C (mmol/L) 2.73 ± 0.68 3.27 ± 0.90 0.009 0.016
HDL-C (mmol/L) 1.29 ± 0.27 1.23 ± 0.22 0.375 -
Apo-A1 (g/L) 1.28 ± 0.30 1.26 ± 0.24 0.758 -
Apo-B (g/L) 0.83 ± 0.22 0.99 ± 0.25 0.011 0.016
Data are means ± SD for pattern A participants (n = 33) and pattern B participants
(n = 31). Means were compared between pattern A and pattern B groups by
independent-Sample T tests. P-values were adjusted for age, gender and BMI by
Binary Logistic Regression.
Kulanuwat et al. Lipids in Health and Disease  (2015) 14:30 Page 4 of 8studied here, only 3/16 (19%) of the non-obese partici-
pants had a pattern B lipid profile whilst 28/48 (58%)
of the obese participants were pattern B; this difference
was highly significant (Table 2).
Interestingly, analysis of the lipid profiles of the pat-
tern A and B participants identified in this study
showed that plasma triglyceride and total cholesterol
concentrations were increased by approximately 40%
and 15% respectively in pattern B participants (Table 3).
Plasma VLDL- and LDL-cholesterol (plus apo-B) con-
centrations were increased in pattern B participants by
50% and 20% respectively, whilst HDL-cholesterol (and
apo-A1) concentrations were similar in pattern A and B
participants (Table 3).
Finally, when expressed as a fraction of the LDL
concentration, total sdLDL-cholesterol (i.e. LDL III +
IV) showed highly significant positive correlations to
BMI, plasma triglyceride concentrations and the tri-
glyceride/HDL-cholesterol ratio (Figure 2). As judged
by r2 values, the most significant correlations were
with plasma triglyceride concentrations and the trigly-
ceride/HDL-cholesterol ratio, and in all cases, correla-
tions were stronger in males than females (Figure 2).Discussion
The ‘gold standard’ methods for studying LDL hetero-
geneity are density gradient ultracentrifugation and
gradient gel electrophoresis which separate LDL sub-
classes on the basis of density and size respectively
[21]. Depending upon the detailed methodology, 3–7
LDL subclasses have been identified by these tech-
niques. Other methods which rely on different princi-
ples include nuclear magnetic resonance, ion mobility
analysis, dynamic light scattering and homogenous as-
says (see [21]). Such varied methods, and the inevit-
able heterogeneity within separated LDL subclasses,
makes comparison of results from different studies ex-
tremely difficult. We chose iodixanol density gradient
centrifugation, not only because it separates LDL sub-
classes on the basis of density, but because iodixanol
gradients are iso-osmotic. This maintains LDL particles in
their native state compared to the inevitable osmotic dam-












ρ < 1.033; Pattern A 13 (81.2) 20 (41.7) 33 (51.6) 0.009
ρ≥ 1.033; Pattern B 3 (18.8) 28 (58.3) 31 (48.4)
Total (%) 16 (100) 48 (100) 64 (100)salt density gradients [20,22]. As a result, the density of
sdLDL reported in this study (LDL III + IV, fractions 7–12
of Figure 1, ρ = 1.036-1.051 g/ml) is lower than that re-
ported from KBr gradients (1.034-1.060 g/ml) [12,18].
A homogeneous assay for sdLDL, based on prior pre-
cipitation of VLDL and lbLDL by heparin and Mg2+ and
subsequent assay of the supernatant using reagents for
the LDL-cholesterol homogeneous assay, was first de-
scribed by Hirano et al. [23]. More recently, the precipi-
tation step has been modified to provide a direct
sdLDL-cholesterol assay suitable for use in large scale
intervention studies [24,25]. Such studies have reported
sdLDL-cholesterol to represent 20-35% of total LDL-
cholesterol with absolute plasma concentrations in the
range 25–75 mg/dl (0.65-1.95 mmol/L) [25-28]. The
results presented here show that sdLDL-cholesterol rep-
resents a somewhat higher proportion of total LDL-
cholesterol; namely 45% for non-obese participants and
54% for obese participants (Table 1). However, the abso-
lute plasma sdLDL-cholesterol concentrations of 1.32
and 1.62 mmol/L for non-obese and obese participants
are within the range given above using the direct
homogeneous assay. Interestingly, a recent study [29]
defined sdLDL as cholesterol at density >1.040 g/ml (by
equilibrium density gradient ultracentrifugation) as
opposed to ≥1.036 g/ml used here; in this case, sdLDL-
cholesterol still represented 30% of total LDL-cholesterol.
Thus, despite the difficulty of comparing results from
different studies, we are confident that the values for
plasma sdLDL-cholesterol concentrations reported here
are comparable to those reported elsewhere.
It was originally thought that sdLDL was formed in the
circulation simply by delipidation of lbLDL [30]. However,
there is now convincing evidence that sdLDL is formed dir-
ectly from precursor lipoproteins secreted by the liver.
Figure 2 Correlation of sdLDL/total LDL ratio with (a) BMI, (b) plasma triglyceride, and, (c) plasma triglyceride (TG)/HDL-cholesterol ratio for all
participants. n = 64, males (n = 20) and females (n = 44). Small dense LDL was defined as LDL III + IV. Correlation p-values and r2 values are given
in each panel.
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occurs in obesity), the liver secretes greater amounts of
large precursor lipoproteins which are delipidated by
lipoprotein lipase and hepatic lipase directly to sdLDL
[13,17]. As a result, plasma sdLDL concentrations are
invariably raised in obesity and to date, most studies
reporting elevated sdLDL concentrations in obesity
have utilized either European or American populations
(see, for example, [14,15,31,32]). However, a recent
study from Korea has reported sdLDL to be elevated in
obese participants, particularly those with large amountsof abdominal visceral fat [33]. To our knowledge, this is
the first study to show that plasma concentrations of
sdLDL-cholesterol are raised in an obese Thai population
(Figure 1, Tables 1 and 2) and that, concurrent with this,
concentrations of lbLDL-cholesterol were correspondingly
decreased. Given that these obese participants had raised
plasma triglyceride concentrations and decreased HDL-
cholesterol concentrations (the atherogenic triad), it is to
be expected that their risk of coronary heart disease
would be increased considerably. It is noteworthy that
the Thai National Health Examination Survey IV (carried
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population of two components of the atherogenic triad,
namely low HDL-cholesterol (<40/50 mg/dl, male/fe-
male) and high triglyceride (>150 mg/dl) to be 47.1%
and 38.6% respectively [34].
An alternative way of analyzing the LDL density data
from this study is to divide participants into pattern A
and pattern B individuals based upon the peak density
of their LDL-cholesterol [20]. Pattern B individuals,
having a LDL-cholesterol peak density of ≥1.033 g/ml,
were much more likely to be obese (Table 2), and had
higher plasma concentrations of total cholesterol, trigly-
ceride, VLDL-cholesterol, LDL-cholesterol and apo-B
compared to pattern A individuals (Table 3). Surpris-
ingly, pattern A and B individuals had similar plasma
concentrations of HDL-cholesterol and apo-A1 (Table 3);
these analytes would be expected to be decreased in pat-
tern B individuals. Given that females are well known
to have higher plasma HDL-cholesterol concentrations
than males [35], one possible explanation for the unex-
pectedly high HDL-cholesterol concentration is that
the pattern B population contained more females.
However, this was not the case and the distribution of
males and females was similar in the pattern A and B
populations (Table 3). Although not measured in the
present study, it is possible that dietary patterns are re-
sponsible for the unexpectedly high HDL-cholesterol
concentrations in the pattern B population. For ex-
ample, populations with a ‘meat and fast food’ dietary
pattern in Korea show similar lipid patterns to the
present study, with high plasma triglyceride concentra-
tions and a decreased prevalence of low HDL-cholesterol
concentrations [36]. In addition, the prevalence of low
HDL-cholesterol has been reported to be significantly
lower in urban areas of Thailand compared to rural areas,
presumably due to different dietary patterns [34].
The association of obesity in a Thai population with
the atherogenic triad is emphasized by the highly sig-
nificant correlations of the sdLDL/LDL ratio with BMI,
plasma triglyceride concentrations and the triglyceride/
HDL-cholesterol ratio (Figure 2). The triglyceride/HDL-
cholesterol ratio is a recently-reported, highly sensitive,
surrogate marker for predicting cardiovascular events
(and insulin resistance) in a variety of metabolic abnor-
malities [37-39].Conclusion
The prevalence of sdLDL in plasma is increased in
obesity in a Thai population such that they demonstrate
a similar atherogenic triad to that previously observed in
European and American populations. It is to be expected
that this would contribute significantly to an increased risk
of coronary heart disease.Methods
Study participants
Plasma samples were derived from a previous study in-
vestigating the occurrence of genetic variants in obese
Thai participants from the Bangkok area [40]. All stud-
ied participants had been informed in writing of the
intended use of their sample and provided written
consent. The intervention studies were approved by the
ethics committee of the Faculty of Tropical Medicine,
Mahidol University REC in accordance with the declar-
ation of Helskinki; reference number MUTM 2012-
030-03. Blood was obtained from participants ≥20 years
old after a 12-hour fast and taken into either acid-citrate-
dextrose (ACD) or EDTA as anticoagulant. Plasma was
obtained by centrifugation and stored at −80°C for up to
1 year before analysis. Body weight was measured using
scales (ZEPPER TCS -150 L, China) and height was mea-
sured using a vertical-measuring rod (Microtoise, Poissy,
France); BMI was calculated as weight (in kg) divided by
height (in m) squared. Participants who had a BMI
≥25 kg/m2 were classified as obese whilst those with a
BMI <25 kg/m2 were assumed to be non-obese [7].
Iodixanol density gradient ultracentrifugation
Density gradients were prepared essentially as de-
scribed by Davies et al. [20] using Optiprep™ (Axis-
Shied PoC AS, Oslo, Norway) which is a commercially
available solution of 60% (w/v) iodixanol and has a
density of 1.32 g/ml. Plasma was adjusted to 12% (w/v)
iodixanol by adding 1.6 ml of plasma (0.8 ml of ACD
plasma + 0.8 ml of EDTA plasma) to 0.4 ml of Opti-
prep™ to give a final density of 1.064 g/ml. A 9% (w/v)
iodixanol solution was prepared by adding 3.0 ml of
Optiprep™ to 17 ml of phosphate –buffered saline
(PBS) to give a final density of 1.048 g/ml. In order to
generate the gradient, 3.4 ml of the 9% (w/v) iodixanol/
PBS solution was transferred to a 4.9 ml Beckman
Optiseal™ centrifuge tube. Using a cannula and syringe,
1.5 ml of the plasma sample made to 12% (w/v) with
iodixanol was under-layered and the tube left for
30 min. Tubes were then centrifuged at 342,000 g at
16°C (deceleration program 5) for 2.5 h in an NVT65.2
near-vertical rotor in a Beckmann L8 ultracentrifuge.
Previous work has shown that storage of plasma sam-
ples for up to 1 year, or mixing of ACD- and EDTA-
plasma samples, had no effect upon the fractionation
of lipoproteins by iodixanol density gradient untracen-
trifugation (data not shown).
Gradients were unloaded from top-to-bottom at a flow
rate of 1 ml/min using a Labconco (Kansas, USA) Auto
Densi-flow density gradient fractionator and harvested as
20 fractions using a Gilson (Luton, UK) FC205 fraction
collector. The refractive index of gradient fractions was
measured using an Abbe 5 refractometer (Bellingham and
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reference to the refractive indices of appropriate iodixanol
density standards.
Laboratory measurements
The cholesterol, triglyceride, apo-A1, and apo-B concen-
trations of plasma samples and gradient fractions were
measured using diagnostic kits (and appropriate calibra-
tors and serum quality controls) supplied by Randox
Laboratories Ltd (Co. Antrim, UK). Analyses were car-
ried out in a SPACE automated analyzer (Schiapparelli
Biosystems, Inc., ENI Diagnostics Division, USA).
Statistical analyses
The independent sample T-test was used to test the mean
difference of plasma lipids and apo-protein concentrations
between obese and non-obese groups, as well as between
LDL-cholesterol peak densities. Data were tested for nor-
mality using the Kolmogorov–Smirnov test and for data
that showed a non-normal distribution, the non-parametric
Mann–Whitney U test was used. Chi-square analysis was
used to analyze the association between LDL-cholesterol
peak density and obesity status. Logistic regression was
used to adjust the data for age, gender and BMI. Pearson
correlation was used to analyze the correlation between
two parameters. In all cases, a P-value of <0.05 was consid-
ered statistically significant and all tests were performed by
SPSS program version 21.
Abbreviations
BMI: Body mass index; lbLDL: Large buoyant LDL; sdLDL: Small dense LDL.
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